The Smith group specializes in developing novel optical technologies and multiomic biomarker discovery for elucidating disease and patient stratification.
Dr Lukas's work focuses on nicotinic acetylcholine receptors, which are relevant to a number of neurological and other diseases, in addition to their roles in nicotine dependence and tobacco-related diseases.